Additionally, the first phase III study (termed as VISION) has also been initiated with an objective of investigating the safety and effectiveness of 177Lu-PSMA therapy against the current standard treatments for patients with progressive PSMA-positive, castration-resistant, postchemotherapy metastatic prostate cancer [32]. Here, FOLH1 is linked to metastatic prostate carcinoma.